COMMUNIQUÉS West-GlobeNewswire

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans
24/01/2024
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
USPTO Grants Registered Trademark Status for "Fiber UP" – An Innovative New Breakthrough In Fiber Supplementation From Glucose Health, Inc. (OTCPK: GLUC)
24/01/2024
BENTONVILLE, Ark., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Glucose Health, Inc., the pioneer in delicious manufacturing prebiotic soluble fiber enriched nutrition beverages, proudly confirms the granting of registered [...]
Kura Oncology Announces Oversubscribed $150 Million Private Placement
24/01/2024
– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma cash, cash equivalents and investments expected to provide runway into 2027 – – [...]
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
24/01/2024
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First demonstration of efficacy in disease-relevant [...]
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
24/01/2024
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling progression to highest dose [...]
Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD
24/01/2024
ROSCREA, Ireland, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in [...]
Tilray Brands Completes Acquisition of Truss Beverage Co.
24/01/2024
Acquisition Solidifies Tilray’s Leadership Position in Cannabis Beverages with ~40% Market Share Truss Facility Bolsters Tilray’s Beverage Operations in Canada LEAMINGTON, Ontario, Jan. 24, 2024 (GLOBE NEWSWIRE) -- [...]
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
24/01/2024
FDA requesting clarifications around chemistry, manufacturing and controls and additional information related to immunogenicity CRL does not impact commercial availability of EGRIFTA SV ® , the F4 formulation of [...]
Theratechnologies reçoit une lettre de non-approbation (CRL) de la FDA concernant son supplément à la licence de produit biologique (sBLA) pour la formulation F8 de la tésamoréline
24/01/2024
La FDA demande des clarifications sur la chimie, la fabrication et les contrôles ainsi que des informations supplémentaires sur l'immunogénicité La CRL n'affecte pas la disponibilité commerciale d'EGRIFTA SV MD , la [...]
CENTOGENE Receives French Research Tax Credit Accreditation
24/01/2024
Partners able to claim up to 30% tax relief CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers [...]
Valhalla’s Innovative Extra Strength Troches Set to Hit Dispensary Shelves Throughout Pennsylvania
24/01/2024
TerrAscend expands its Valhalla product lineup to include one of the first 100mg edibles in The Keystone State TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) ( [...]
RadNet’s Arizona Diagnostic Radiology Group Joint Venture Acquires Seven Outpatient Imaging Centers in Phoenix, Arizona
24/01/2024
LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that its joint ventured [...]
EmpowerHER: A new professional network for female leaders in health launches
24/01/2024
OTTAWA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The EmpowerHER Leadership Network proudly unveils its innovative networking platform, marking a transformative milestone in championing and supporting women within Canadian [...]
KFSH&RC Celebrates 25 Scientists Named in Stanford's Top 2% Most-Cited Researchers Worldwide
24/01/2024
RIYADH, Saudi Arabia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre honored 25 scientists who joined Stanford University's prestigious list, marking them among the 'top 2% most- [...]
Fighting leprosy with artificial intelligence: DAHW and Belle.ai join forces with Senegal’s Ministry of Health and Social Action to detect and combat neglected diseases
24/01/2024
WÜRZBURG, Germany and CAMBRIDGE, Mass., Jan. 24, 2024 (GLOBE NEWSWIRE) -- DAHW German Leprosy and Tuberculosis Relief Association and BelleTorus Corporation (“Belle.ai”) have joined forces with Senegal’s Ministry of [...]
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
24/01/2024
Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of Libmeldy® ( [...]
Coloplast Finance B.V. - Change of Auditor
24/01/2024
Today, 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting at which Ernst & Young Accountants LLP was elected as Coloplast Finance B.V.’s auditors. Attachment [...]
Coloplast Finance B.V. - Decisions at the Annual General Meeting
24/01/2024
On 24 January 2024, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2022/23. In addition, [...]
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
24/01/2024
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and Adaptate Biotherapeutics) and Dr Inga Deakin (Molten Ventures) [...]

Pages